Key result
The mRNA-1273 vaccine induced potent neutralizing antibody and CD8 T cell responses and protected against SARS-CoV-2 infection in the lungs and noses of mice without immunopathology.
Why the study?
A SARS-CoV-2 vaccine was urgently needed to control the global COVID-19 public health crisis.
Answers are grounded in this paper and cite their sources.
Supports advancement to human trials; extends mRNA platform data to SARS-CoV-2 protection without immunopathology.
A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation.
No takes yet. Share an insight, caveat, or question.
Corbett et al. (2020) studied SARS-CoV-2 infection. mRNA-1273 was evaluated on Neutralizing antibody and CD8 T cell responses and protection against SARS-CoV-2 infection. The mRNA-1273 vaccine induced potent neutralizing antibody and CD8 T cell responses and protected against SARS-CoV-2 infection in the lungs and noses of mice without immunopathology.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: